4-Pivaloylimidazol | 61985-31-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Pivaloylimidazol
• 英文别名: 1-(1(3)H-imidazol-4-yl)-2,2-dimethyl-propan-1-one；1-(1H-Imidazol-4-yl)-2,2-dimethylpropan-1-one；1-(1H-imidazol-5-yl)-2,2-dimethylpropan-1-one
• CAS: 61985-31-7
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: YHKNXNLDHRCTLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20080050336A1

  公开（公告）日：2008-02-28

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Bachand Carol

  公开号：US20090068140A1

  公开（公告）日：2009-03-12

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还揭示了含有这些化合物的制药组合物和使用这些化合物治疗HCV感染的方法。
• Indole and Benzimidazole Derivatives
  申请人：Boyce Rustum S.

  公开号：US20080317744A1

  公开（公告）日：2008-12-25

  The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的吲哚和苯并咪唑化合物及其药学上可接受的盐、酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。本发明的化合物具有以下一般式：
• Methods and compositions for inhibition of Ras
  申请人：ARAXES PHARMA LLC

  公开号：US10011600B2

  公开（公告）日：2018-07-03

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了 Ras 蛋白的抑制剂、调节 Ras 蛋白活性的方法以及治疗由 Ras 蛋白介导的疾病的方法。描述了一种用化合物调节 K-Ras、H-Ras 或 N-Ras 突变蛋白活性的方法。可治疗的疾病包括癌症，如血癌、胰腺癌、MYH 相关性息肉病、结直肠癌或肺癌。
• Substituted quinazoline compounds and methods of use thereof
  申请人：Araxes Pharma LLC

  公开号：US10351550B2

  公开（公告）日：2019-07-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构 (I)： 或其药学上可接受的盐、立体异构体或原药，其中 R、R1、R2a、R2b、R2c、A、B、L1 和 E 如本文所定义。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节G12C突变型KRAS蛋白活性以治疗疾病（如癌症）的方法。